Testosterone injections for men with low testosterone and early prostate cancer
Tests testosterone injections in men with low testosterone and early prostate cancer.
Key facts
- Who runs it
- University of Miami
- Where
- Miami, United StatesSee the 2 sites
- Trial code
- Registry title
- Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 35 people, planned
- Starts
- 30 Nov 2026
- Expected to end
- 31 May 2032
- Type of study
- Interventional
- Treatments tested
- Testosterone cypionate
- Record updated
- 2 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with newly diagnosed low-risk prostate cancer on active surveillance who also have low testosterone and symptoms. It tests whether testosterone replacement is safe.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Newly diagnosed low-risk prostate cancer, on active surveillance, confirmed by MRI-guided biopsy
- Earlier treatment
- No testosterone replacement therapy in the past year and not using it now
- Biomarker or test result
- Two testosterone levels below 350 ng/dL, taken before 10am, 24 hours to 90 days apart; symptom score (Aging Male's Symptoms Score) above 27
Main reasons for not taking part
- Gleason score 7 (Grade Group 2) prostate cancer or higher
- PSA above 10 ng/mL at the start
- Hematocrit above 51% at the start
- T3 or T4 disease
- Unstable angina or a history of breast cancer
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Males aged ≥ 18 years old
- Newly diagnosed with low-risk prostate cancer initially confirmed by fusion guided prostate biopsy (transrectal or trans perineal) by multiparametric MRI
- Males diagnosed with low-risk prostate cancer on active surveillance
- Two confirmatory testosterone levels <350 ng/dL (taken before 10am), with at least 24 hours and no more than 90 days between the two tests
- Symptoms of low testosterone (Aging Male's Symptoms Score >27)
- Able to obtain Testosterone medication through insurance or out-of-pocket
- Willing and able to provide written informed consent and able to comply with study requirements
Who cannot take part
- Unable or unwilling to obtain Testosterone medication through insurance or out-of-pocket
- History of Testosterone Replacement Therapy (TRT) within the past year
- Diagnosis of Gleason score 7 (Grade Group 2) prostate cancer or higher on diagnostic or confirmatory biopsy
- T3 or T4 disease
- Unstable angina
- History of breast cancer
- Any other condition or situation which, in the opinion of the investigator, could impact patient safety, prevent successful data collection, or reduce the likelihood of successful study participation
- Males <18 years old
- Current use of TRT
- PSA >10 ng/mL at baseline
- Hematocrit > 51% at baseline
- Unable or unwilling to provide informed consent or comply with study requirements
Where in United States
- Desai Sethi Urology InstituteMiami, United StatesContact: Thomas Masterson (principal investigator)Taking people
- Sylvester Comprehensive Cancer Center*Miami, United StatesContact: Bruce Kava (principal investigator)Taking people
About the trial
What the trial wants to find out
The purpose of this study is evaluate the safety of testosterone replacement therapy in men with newly diagnosed low-risk prostate cancer and hypogonadism on active surveillance.
The group in the trial
- Testosterone cypionateTreatment being tested
Participants will self-inject 100mg of testosterone cypionate once per week for 12 months
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Safety of Intramuscular Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance
- Plain-language title
- Testosterone injections for men with low testosterone and early prostate cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 2 November 2026